Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results
7 augusti, 17:30
Press Release – No. 11 / 2025
Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results
Copenhagen, Denmark, August 7, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on August 14, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the second quarter of 2025.
Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; Chief Medical Officer, David Kendall; and Chief Commercial Officer, Eric Cox. The presentation will be followed by a Q&A session.
The live listen-only audio webcast of the call and accompanying slide presentation will be accessible at https://edge.media-server.com/mmc/p/w964yrhw . To receive telephone dial-in information and a unique personal access PIN, please register at https://register-conf.media-server.com/register/BI38dbf0632d0e4bcfa7d2cd384405fa1f. Participants are advised to register for the call or webcast approximately 10 minutes before the start. A recording of the event will be available following the call on the Investor section of Zealand Pharma’s website at https://www.zealandpharma.com/investors/events-presentations/.
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.
Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand Pharma’s business and activities, please visit www.zealandpharma.com.
Contacts
Adam Lange (Investors)
Vice President, Investor Relations
alange@zealandpharma.com
Neshat Ahmadi (Investors)
Investor Relations Manager
neahmadi@zealandpharma.com
Anna Krassowska, PhD (Investor and Media)
Vice President, Investor Relations & Corporate Communications
akrassowska@zealandpharma.com
Ämnen i artikeln
Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results
7 augusti, 17:30
Press Release – No. 11 / 2025
Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results
Copenhagen, Denmark, August 7, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on August 14, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the second quarter of 2025.
Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; Chief Medical Officer, David Kendall; and Chief Commercial Officer, Eric Cox. The presentation will be followed by a Q&A session.
The live listen-only audio webcast of the call and accompanying slide presentation will be accessible at https://edge.media-server.com/mmc/p/w964yrhw . To receive telephone dial-in information and a unique personal access PIN, please register at https://register-conf.media-server.com/register/BI38dbf0632d0e4bcfa7d2cd384405fa1f. Participants are advised to register for the call or webcast approximately 10 minutes before the start. A recording of the event will be available following the call on the Investor section of Zealand Pharma’s website at https://www.zealandpharma.com/investors/events-presentations/.
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.
Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand Pharma’s business and activities, please visit www.zealandpharma.com.
Contacts
Adam Lange (Investors)
Vice President, Investor Relations
alange@zealandpharma.com
Neshat Ahmadi (Investors)
Investor Relations Manager
neahmadi@zealandpharma.com
Anna Krassowska, PhD (Investor and Media)
Vice President, Investor Relations & Corporate Communications
akrassowska@zealandpharma.com
Ämnen i artikeln
Analys
Novo Nordisk
Bostadsmarknaden
Trumps handelskrig
Inflationen
.jpg&w=3840&q=75)
Fonder
Aktieråd
Analys
Novo Nordisk
Bostadsmarknaden
Trumps handelskrig
Inflationen
Fonder
Aktieråd
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
